PTIX - Protagenic Therapeutics says board approved 1-for-4 reverse stock split

2023-03-22 16:09:07 ET

• Protagenic Therapeutics ( NASDAQ: PTIX ) on Wednesday announced it has approved a 1-for-4 reverse stock split of the company's issued and outstanding common stock.
• The reverse stock split will not reduce the number of authorized shares of common stock or change the par values of the common stock.
• The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the company's shares of common stock.
• All outstanding options, warrants, and similar securities entitling their holders to receive or purchase shares of common stock will be adjusted as a result of the reverse stock split, as required by the terms of each security.
• Press Release .

For further details see: